TScan Therapeutics, Inc. (TCRX) Financials
Annual revenue, profitability and per-share results for TScan Therapeutics, Inc., as reported in SEC filings.
Revenue • FY2025
$10.32M
▲ 266.7%YoY
Net income • FY2025
-$129.77M
▼ 1.8%YoY
Diluted EPS • FY2025
$-1.00
▲ 12.3%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $10.32M | -$129.77M | — | $-1.00 | -$139.73M | -1315.4% | +266.7% |
| FY2024 | $2.82M | -$127.5M | — | $-1.14 | -$114.65M | -4787.7% | -86.6% |
| FY2023 | $21.05M | -$89.22M | — | $-1.36 | -$64.5M | -444.0% | +55.5% |
| FY2022 | $13.54M | -$66.22M | — | $-2.75 | -$70.73M | -492.3% | +33.5% |
Figures as reported in TScan Therapeutics, Inc.'s 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a TCRX filing.
Get an email when TCRX files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.